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Abstract
Introduction: Treatment of acute kidney injury (AKI) is a complex current problem. Mortality in this pathology is 
over 50%. One of the areas of correction therapy in AKI patients is the improvement of diagnostics and the earliest 
identification of the underlying cause of AKI. The second promising direction in reducing mortality is prevention of 
AKI progression (nephroprotection) and resulting multi-organ disorders by individual pharmacological and non-phar-
macological intensive therapy.
Objectives: to evaluate the possibilities of individual pharmacological correction and intensive care of patients with 
AKI of different origin.
Materials and methods: A prospective nonrandomized study. Inclusion criteria: patients with prerenal, renal and 
subrenal AKI module in stage of oligoanuria and restoration of diuresis. Exclusion criteria: AKI in patients after car-
diosurgery and operations on large vessels. Individual pharmacological and non-pharmacological correction (renopro-
tection) was performed in 250 ICU patients with prerenal (130), renal (81) and subrenal (39) AKI. The effectiveness of 
individual nephroprotection was assessed by the duration of the oligoanuria stage (indicator of AKI severity).
Results and discussion: The basis of intensive therapy in AKI patients was renal replacement therapy and peridialysis 
care. Peridialisys support was presented by a complex of therapeutic measures aimed at preventing the progression of 
AKI (nephroprotection) and the prevention of multi-organ complications. Individual pharmacological and non-phar-
macological peridialysis intensive therapy was performed, including: removal of the main cause of forming AKI; 
maintenance of normal circulation blood volume and effective cardiac output; maintenance of adequate lung ventilation 
(correction of hypoxia, timely ventilation); correction of hypertension, hypotension, and clinically significant arrhyth-
mia; improvement of renal blood flow and stimulation of diuresis; stopping bleeding and correction of anemia; targeted 
antibiotic therapy; removal or adequate drainage of the intoxication focus (purulent focus); use of alternative ways of 
detoxication and efferent methods. It was proved that individual pharmacological and non-pharmacological nephro-
protection made it possible to improve the results of treatment. The duration of the oligoanuria stage significantly (p < 
0.05) decreased to 14.3±0.9 days in the main group (22.6±1.2 days in the comparison group).
Conclusions: The medical technology of individual intensive therapy with renal replacement  therapy and peridialysis 
care has been developed, including: a diagnostic stage with determination of peculiarities of renal hemodynamic dis-
orders and pharmacological and instrumental (stenting, drainage, etc.) correction of the real cause and manifestations 
of AKI. Improving AKI diagnostics and carrying out individual pharmacological and non-pharmacological correction 
improves the results of AKI treatment.
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Introduction
Treatment of AKI is an important social problem. The 
incidence of AKI has increased, accounting for more 
than 35% of patients in intensive care units (ICU) (Ake 
et al. 2005, Case et al. 2013). More often, it develops as a 
component of multi-organ failure (MOF) (Jo et al. 2007, 
Kellum and Decker 2001, Lauschke et al. 2006 ). AKI is 
an independent predictor of adverse outcome in critically 
ill patients and increases hospital mortality 3–10 times 
(Lameire et al. 2005, Overberger et al. 2007, Ostermann 
and Chang 2007).
Mortality in this pathology remains high and exceeds 
50% (Vaira et al. 2001, Vijayan and Palevsky 2012). Of-
ten the difficulty of conducting adequate intensive care is 
associated with the lack of timely diagnosis and the late 
establishment of the real cause of AKI (Wystrychowski 
et al. 2009, Tomilina 2011). The first part of this paper 
presents the data on the evaluation of the state of renal he-
modynamics, using the Doppler method in patients with 
AKI. The study of renal hemodynamics made it possible 
to improve diagnostics and establish the immediate cause 
of AKI. The necessity of individual pharmacological and 
non-pharmacological nephroprotection in these patients 
was proved.
In AKI patients, a harmonious nephroprotection sys-
tem is not developed. There are some works where ne-
phroprotective measures are presented as the use of sin-
gular medicines in individual cases. Many issues remain 
controversial; mutually exclusive views are often have to 
be dealt with. For example, several authors oppose the 
use of dopamine in the ICU for the prevention and treat-
ment of AKI (Kolesnik 2010, Kellum and Decker 2001, 
KDIGO 2012, Lauschke et al. 2006). Others evaluate 
positively the experience of using this drug, especially in 
prerenal AKI (Bellomo et al. 2000, Saito et al. 2011). At 
the same time, it has been proposed to use erythropoietin 
and iron to correct anemia. According to KDIGO, it is 
not recommended to use diuretics for the prevention and 
treatment of AKI, although in cardiorenal and hepatore-
nal syndromes the use of diuretics for both prophylaxis 
and treatment of AKI is justified, ensuring a steady in-
crease in the rate and volume of diuresis and a decrease 
in azotemia.
Improvement of pharmacological and nonpharmacolo
gical correction to achieve  nephroprotection in patients 
with various AKI modules is carried out in ICU of the 
Donetsk Clinical Territorial Medical Unit (DoCTMU) 
(Shramenko and Shkarbun 2011, Shramenko and Shkar-
bun 2014).
Objectives
To evaluate the opportunity of individual pharmacologi-
cal correction and intensive care in patients with different 
AKI stages.
Material and methods
250 patients were the main group (treated from 2009 to 
2014 in DoCTMU): 162 male (64.7%) and 88 female 
(35.3%). The age was from 18 to 85 years, an average of 
53±8.2. At the time of admission to the ICU, isolated AKI 
was only 5%. All the patients after diagnosis clarification 
were divided into modules: 1) patients with prerenal AKI 
module (130); 2) patients with renal module AKI (81); 3) 
patients with subrenal AKI module (39). The module was 
a relationship of etiology, pathogenetic mechanisms, risk 
factors, and causes of AKI.
The comparison group consisted of 107 patients with a 
prerenal (60), renal (32) and subrenal (15) variant of AKI 
treated at the DoCTMU before 2009, aged 18 to 77 years, 
an average of 48±7.9. Of which 74 were males (69.2%) 
and 33 – females (30.8%). Upon admission to the ICU, 
isolated AKI amounted to 25%. Dialysis treatment was 
performed in 79 patients (73.8%). In the comparison 
group, treatment was performed without individual phar-
macological and non-pharmacological nephroprotection.
Statistical processing of data
The analysis of the results was carried out in statistical 
packages MedStat v.4.1 (Lyakh and Guryanov 2012), 
MedCalc v. 13.2.2 (MedCalc SoftWare bvba, 1993–
2014), and Statistica Neural Networks v.4.0 B (StatSoft 
Inc., 1996–1999). 
For the analysis, methods of constructing multivaria-
te models of classification were used. The quality of the 
constructed models was estimated by their sensitivity and 
specificity, a 95% confidence interval (95% CI) was cal-
culated. To determine the factors most associated with the 
results of treatment, the “genetic algorithm” (GA) method 
was used. To assess the adequacy of multivariate mathe-
matical models and predictive cure rate tests, Area Under 
Curve (AUC) of their 95% CI was used. To evaluate the 
possibility of using the constructed models on new data, a 
method was used to verify their prognostic characteristics 
on the confirming variety (a random number generator was 
used for the selection). To assess the degree of influence 
of factor characteristics on the resulting characteristics, 
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a method of constructing logistic regression models was 
used. For the assessment, the odds ratio (OR), as well as 
their 95% CI, was calculated (Lyakh and Gurianov 2012, 
Petri and Sabin 2003).
Results and discussion
Intensive therapy in AKI patients integrated renal re-
placement therapy (hemodialysis) and peridialysis care. 
The peculiarities  of intensive care were determined by 
the AKI module. However, even within the module, an 
individual approach was required.
The basis of peridialysis intensive care was thera-
peutic measures aimed at preventing the progression of 
renal damage (nephroprotection) and the prevention of 
multi-organ failures (MOF).
Peridialysis intensive therapy included: removing  the 
cause of AKI; maintenance of normovolemia and effective 
cardiac output; maintenance of adequate lung ventilation 
(correction of hypoxia, timely lung ventilation); correction 
of hypertension, hypotension, and clinically significant 
arrhythmia; improvement of renal blood flow and stim-
ulation of diuresis; stopping bleeding and correction of 
anemia; targeted antibiotic therapy; removal or adequate 
drainage of the intoxication focus (purulent focus); use of 
alternative ways of detoxication and efferent methods.
Peridialysis support was represented by pharmacologi-
cal and non-pharmacological measures. Pharmacological 
intensive therapy was aimed at improving renal blood 
flow and stimulating diuresis and included: first of all, 
maintenance of blood volume with adequate infusion me-
diums, administration of drugs that improve renal blood 
flow (pentoxifylline, dipyridamole, dopamine, xanthinol 
nicotinate, euphyllin) and diuresis stimulating (furose-
mide, torasemide, xypamide); stopping bleeding (etamzi-
late sodium, tranexamic acid, novoseven, octaplex) and 
correction of anemia (transfusion of blood components, 
and the prescription of erythropoietin for patients with 
AKI having сhronic kidney insuffciency (CKI)); antibac-
terial therapy, maintenance of analgesia, etc. Non-phar-
macological nephroprotection was aimed at: prompt res-
toration of urine passage (stenting, nephrostomy, removal 
of stones, tumors, etc.); instrumental improvement of sys-
temic blood flow (counterpulsation in cardiogenic shock, 
puncture of the pericardium in  tamponade and severe ex-
udative pericarditis, endovascular intervention in renal ar-
tery thrombosis or stenosis, etc.); early removal or drain-
age of purulent focus; cooling, elastic bandaging in the 
distal direction, and immobilization in a crush- syndrome.
Among the general principles of peridialysis support 
were the following: the restrictive infusion therapy and 
other fluid intake, taking into account renal and extrare-
nal losses; correction of cardiovascular disorders with a 
sufficient cardiac output, cardiac index not less than 2.8 
L/min/m2; prevention of hypoxia, timely artificial lung 
ventilation with maintenance of SpO2≥90%; correction of 
anemia with maintaining a hemoglobin level of at least 85 
g/L; preventive (before the appearance of symptoms of 
mucosal lesions) protection of the gastrointestinal tract by 
injection forms of antisecretory drugs; use of alternative 
ways of detoxification (gastrointestinal lavage, therapeu-
tic diarrhea, etc.); and mandatory drainage and sanation 
of the intoxication focus in order to stop the damaging 
effect on the kidneys. Regardless of the AKI module, the 
general principle of nephroprotection was excluding ad-
ministration of nephrotoxic drugs.
The main principles of intensive care in AKI patients 
are presented in Table 1.
Algorithm of individual intensive care
Diagnostics of an AKI module and verification of its im-
mediate cause, taking into account risk factors and using 
modern visualization and laboratory methods.
Impact on the cause of AKI in order to restore the rate 
of diuresis and daily diuresis: replenishment of blood vol-
ume (BV); removal and inactivation of  toxic substances; 
Table 1. The main principles of intensive care in AKI patients
№ Principles, determined by 
the clinical situation
Appropriate intensive care The universal 
principle
1. Arrest of pathogenic action 
of the ethiologic factor
Stopping bleeding, removal of exo- and endotoxines, surgical lavage of 
purulent focus, restoration of blood circulation in  vessels, restoration of 
urine passage, etc.
Nephroprotection. 
Prevention of MOF
2. Pathogenic preventive 
therapy of complications
Prevention of hypoperfusion, hypoxia, correction of anemia, prevention 
of bleeding, antibiotic therapy, etc.
3. Replacement  and 
supporting therapy
Renal replacement therapy, artificial lung ventilation, alternative ways 
of detoxication, efferent methods (extracorporeal antibiotic therapy, 
ultraviolet irradiation, plasmapheresis)
4. Syndrome therapy in life-
threatening situations
Cardiopulmonary resuscitation,
correction of cardiac rhythm disturbances, normalization of blood 
pressure, reduction of pulmonary edema, correction of hemorrhagic 
complications, etc.
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unblocking the kidney and urinary tract; stimulation of 
diuresis with diuretics and drugs improving renal blood 
flow; alkalization of plasma and urine on therapeutic 
grounds; X-ray endovascular intervention with stenting 
and selective thrombolysis, etc.
Prevention the development or progression of multi-or-
gan failures: 1) prevention of  hypoxia, timely respiratory 
support; 2) prevention and correction of infectious com-
plications, both conservatively and by plasmapheresis 
with extracorporeal antibiotic therapy with a broad 
spectrum of powerful targeted antibiotics (de-escalation 
variant), ultraviolet blood irradiation; 3) prevention of 
fatal hyperkalemia and correction of dyselectrolytemia; 
4) prevention and correction of cardiovascular disorders 
(antihypertensive drugs, cardioprotectors, antiarrhythmic 
drugs); 5) prevention and treatment of hemorrhagic com-
plications; preventive (before any symptoms of mucosa 
damage appear) protection of the gastrointestinal tract by 
injection forms of H2-histamine receptors blockers and 
proton pump inhibitors; prescription of a complete com-
plex of  haemostatic agents, including octaplex; 6) paren-
teral nutrition (including nephrotect).
Timely implementation of replacement renal therapy 
when creating conditions for the most effective and safe 
treatment (drainage or removal of the focus of intoxica-
tion, correction of hemodynamic disorders, etc.).
The medical technology of individual renal replace-
ment therapy with peridialysis care, developed on the ba-
sis of the improved diagnostics, includes several stages.
Сtage I. Optimized diagnosis of AKI
Identification and clarification of the cause of AKI based 
on: anamnesis, clinical picture of the disease; clinical and 
laboratory parameters; data of a complex renal ultrasono-
graphy with ultrasound dopplerography; if necessary, CT, 
MRI, echocardiography, etc.
Assessment of AKI severity by SAPS, RIFLE sca-
les according to clinical and laboratory data, including 
s-NGAL and dopplerographic renal blood flow parame-
ters. Determination of prerenal, renal or subrenal modu-
les of AKI. Differentiation of genuine prerenal AKI and 
prerenal AKI by cause factor. Consultations with relevant 
specialists: urologist, cardiosurgeon, nephrologist, thora-
cic surgeon, vascular surgeon, transplantologist, etc.
Stage II. Optimized Intensive care of AKI
Pre-dialysis: 1) removal of AKI cause; 2) in patients 
with prerenal and renal AKI, keeping normal BV, im-
provement of renal blood flow and stimulation of diu-
resis; prevention of hypoxia, timely respiratory support, 
maintenance of oxygenation and cardiac output according 
to protocols. Twenty-four-hour testing for dosage and 
effecacy of some drugs, such as dopamine, furosemide 
to assess the possibility of restoring kidney function; in 
patients with  genuine perenal AKI, depending on the 
immediate cause, certain measures are to be taken:  resto-
ration of BV by targeted infusions of, for example, 2.5% 
sodium chloride solution;  pericardial puncture, renal arte-
ry stenting, etc.); 3) in patients with subrenal AKI – urgent 
restoration of urine passage  (stenting, nephrostomy, etc.).
Renal Replacement Therapy. Hemodialysis and its mo-
difications.
Daily individual hemodialysis regimen and dosing. The 
decision to start hemodialysis therapy has to be based on 
the analysis of a specific clinical situation, the vollemic, 
electrolyte and metabolic statuses of the patient, includ-
ing renal blood flow and s-NGAL. Priority must be given 
to short (2.5-3 hours), frequent (daily, every other day) 
hemodialyses with peridialysis intensive therapy, aimed 
at the prevention of dialysis disequilibrium syndrome, 
cardiovascular, hemorrhagic and other complications. 
Early or prophylactic hemodialyses should be performed 
only in patients with toxic nephropathy. In other cases, 
safe conditions for the procedure should be provided: 
stabilization of hemodynamic parameters, correction and 
prevention of hemorrhagic complications, sanation of the 
purulent focus by drainage or surgical removal. Alterna-
tive ways of detoxication are to be used. If there are puru-
lent septic complications, severe endogenous intoxication 
(crush syndrome, destructive pancreatitis, leptospirosis, 
etc.) and autoimmune diseases, hemodialysis needs to be 
combined with extracorporeal antibiotic therapy, plasma-
pheresis, ultraviolet blood irradiation.
Individual tactics of intensive care in accordance with 
immediate cause of AKI
If the immediate cause of AKI is diagnozed, early targeted 
intensive care can be provided. As examples  of individu-
al intensive care, patients with some diagnoses in diffe-
rent modules are presented:
Prerenal AKI: 1) rhabdomyolysis; 2) renal artery 
thrombosis in solitary functioning kidney; 3) hypovole-
mic shock due to loss of water and electrolytes;
Renal AKI: toxic nephropathy;
Subrenal AKI due to bilateral (usually, with a solitary 
functioning kidney) or unilateral block and absence of 
urine passage.
Prerenal AKI module
In the group of patients with rhabdomyolysis (RM) of any 
origin, targeted intensive care included: early hemodiluti-
on and alkalization of plasma (to shorten the duration of 
the oligoanuria stage, to reduce the need for dialysis tre-
atment and to improve the outcome of AKI). Nephropro-
tection in RM also included adequate analgesia, improve-
ment of the rheological properties of the blood, correction 
of hemodynamic and respiratory disorders, stimulation of 
the gastrointestinal tract, and the use of efferent methods. 
Stripe incisions in the damaged areas of the body in com-
pression syndrome were not a nephroprotective measure. 
They were complicated by bleeding, infecting and did not 
shorten the duration of oliguria.
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In the group of patients with renal artery thrombosis of 
solitary functioning kidney, the individual intensive care 
included the following steps.
1. Diagnosis. The reasons for diagnosing renal artery 
thrombosis were: clinical manifestations – back pain, 
oliguria; risk factors: atherosclerosis, hypertension, 
permanent atrial fibrillation, anamnesis of myocardial 
infarction or transient ischemic attack, malignant neo-
plasms, old age, cirrhosis of one of the kidneys. 
2. The assignment of renal ultrasound examination in the 
regime of Doppler mapping, as one of the modern vi-
sualization methods, made it possible to diagnose renal 
thrombosis to high precision, quickly and safely. Kid-
ney ultrasound in the usual regime was non-informa-
tive in this pathology. 
3. Carrying out X-ray endovascular intervention, including 
several stages: catheterization of the renal artery; tro-
moboaspiration and balloon angioplasty of the vessel; 
selective thrombolysis (actilize 100 mg for 1 hour). 
Endovascular intervention was advisable despite the 
duration of oligoanuria, as in this case  AKI was pre-
renal (formation of collaterals, preservation of tubular 
epithelium and parenchyma). High level  of plasma cre-
atinine  was not a counterindication for the introduction 
of radiocontrast agents.
In all 13 patients of this group, diuresis was recovered 
immediately after the endovascular intervention, despite 
prolonged anuria (up to 7 days). Hemodialysis was not 
required. Such a nephroprotective therapy was organ-pre-
serving; it prevented cirrhosis of the kidney and the need 
for program hemodialysis and provided a good quality of 
life for the group of patients. with extremely severe mo-
dule of the sisease.
Individual tactics of intensive care was used in patients 
with AKI due to loss of water and electrolytes. The main 
diagnosis at admission was established only in 52% of 
patients. In order to clarify the diagnosis, the immedia-
te cause and severity of AKI, all patients had ultrasound 
dopplerography applied, if necessary, CT of the abdomi-
nal cavity and fibrogastroscopy were conducted. In re-
trospect, the patients were divided into 2 subgroups, ac-
cording to the degree of disturbance of renal blood flow. 
According to the dopplerography data, 23 patients did 
not have severe disorders of blood flow in their kidneys. 
Although Vps was below normal (58±2.3 cm/sec), Ved 
did not decrease significantly, being on averahe 20±1.6 
cm/sec. Thus, the systolic-diastolic ratio remained within 
the normal values of 2.9. Along with the rates of arterial 
blood flow, RI was within 0.65±0.2, which did not differ 
significantly from the data in the control group. 
Such a state of renal blood flow testified against severe 
damage to the renal tubules and parenchyma, which made 
it possible to perform conservative nephroprotective 
therapy, despite an increase in plasma creatinine above 
600 μmol/L. The therapy was aimed at replenishment of 
BV and correction of dyselectrolytemia. Infusion thera-
py included 2.5% sodium chloride solution 4ml/kg/day, 
sterofundin – 6 ml/kg/day, GIK – 8ml/kg/day. The lack 
of potassium was restored with intravenous administrati-
on of potassium chloride, asparcam, and panangin, with 
daily monitoring the laboratory parameters. Gastrointes-
tinal lavage with enterosoption and cleansing enema was 
used twice a day. Within 24 hours, there was a decrease 
in the levels of urea by 10.0±1.4 mmol/L and creatinine 
by 30-40 μmol/L in this subgroup. Within 2-3 days, such 
a therapy led to recovery of diuresis and a decrease in 
azotemia.
In 9 patients, a significant worsening of renal blood 
flow was detected according to the data of dopplerograp-
hy. Vps and Ved were reduced to 52.0±2.3 and 11.1±1.3 
cm/s, respectively. RI was 0.79±0.03, indicating a severe 
form of AKI, although the indicators of urea and creatini-
ne were comparable to those in the subgroup with relati-
vely preserved renal blood flow. After the diagnosis was 
clarified, 7 patients of this subgroup had to undergo a sur-
gical intervention (gastrectomy – 3, drainage of omental 
bursa – 3, removal of the gall bladder –1). In 4 patients, 
despite complex intensive therapy, diuresis did not reco-
ver. Renal replacement therapy was started, which was 
combined with plasmapheresis and extracorporeal antibi-
otic therapy. The mortality rate was 9.3%. A 30-day sur-
vival rate was 100%.
So, individual tactics of nephroprotection in this sub-
group included: 1) assessment of kidney  hemodynamic 
disorders and  possibility for conservative renal blood 
flow restoration; 2) correction of dyselectrolytemia (2.5% 
solution of sodium chloride, GIK, sterofundin); 3) creati-
on of conditions for safely renal replacement therapy (re-
moval or drainage of the purulent focus, restoration of pa-
tency of the gastrointestinal tract, etc.); 4) increasing the 
effectiveness of antibiotic therapy by combining hemodi-
alysis with plasmapheresis and extracorporeal antibiotic 
therapy by means of powerful antibiotics (de-escalation 
variant); 5) parenteral nutrition (including nephrotect).
Thus, only within the group of AKI caused by the loss 
of water and electrolytes, various renal hemodynamic 
disorders were revealed. Tactics and success of nephro-
protection and intensive care depend on the ability of the 
kidneys to restore, and a need for surgery to restore the 
function of other organs in order to stop their damaging 
effects on the kidneys.
Renal module AKI
The largest subgroup of renal AKI was represented with 
the patients with toxic nephropathy (57). Of these, 15 
were poisoned with toxic substances, and 42 had drugs 
nephropathy. The lowest blood flow rates and the hig-
hest RI were found in the group of patients with toxic 
nephropathy. A decrease in Vps and Ved in this group re-
ached 32 and 1.7 cm/s, respectively, and the RI increased 
to 0.95. The thickness of the parenchyma, according to 
renal ultrasound, was more than 2.5 cm, and in some pa-
tients reached 3.5 cm. Echogenicity of the parenchyma 
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was higher in all the patients. s-NGAL at admission was 
32.99±0.34 ng/ml (13.6±0.8 in the control group), which 
was significantly higher than in the subrenal and prerenal 
AKI groups. The above indicated a severe damage to the 
renal tubulointerstitial apparatus and was  confirmed by 
the longest stage of oligoanuria, up to 30 days. All the pa-
tients with such disorders need renal replacement therapy.
Nephroprotection, in order to shorten the duration of 
the oligoanuria stage and to reduce the duration of dialysis 
therapy, included the following measures. The key point of 
nephroprotection was the early removal of the poisonous 
substance, both by conservative measures (tube lavage, 
gastrointestinal lavage, cleansing enema, enterosorption), 
and active detoxication methods (early hemodialysis, plas-
mapheresis). In the toxicogenic stage antidote therapy 
(unitiol, tetacin-calcium, sodium thiosulfate, acetylcyste-
ine) was used. In a number of cases, gastrointestinal lavage 
and therapeutic diarrhea were sufficient to stabilize the pa-
tients’s condition. Due to such a therapy, in some patients 
plasma urea levels could decrease by more than 10 mmol/L 
per day and the level of creatinine – by 30-40 μmol/L. Hy-
perhydration was also corrected, as well as events of pul-
monary edema, by means the alternative removal of fluid 
through the gastrointestinal tract. The parameters of renal 
hemodynamics, according to the data of Dopplerography , 
were restored within 2-3 weeks and were not significantly 
different from those of the control group.
The peculiarity of toxic AKI because of taking medi-
cines (in more than 70% of cases) was the development 
of medical nephropathy on the background of initially un-
avoidable risk factors (old age, CKD, diabetes, severe hy-
pertension, etc.). In 50% of patients, there were avoidable 
risk factors: dehydration, anemia, hypotension, hyper-
thermia, recent use of radiocontrast agents, long-term an-
tibiotic therapy, repeated use of rifampicin. combination 
of several nephrotoxic drugs and taking anti-viral drugs 
(acyclovir). In ultrasound examination of kidneys in pa-
tients of stage I, it was revealed an increased thickness of 
the parenchyma over 2.6 cm, increased echogenicity of 
the kidneys; some patients had punctate granular deposits 
in the parenchyma (signs of interstitial nephritis).
Nephroprotective therapy in this subgroup can be pre-
sented by the patients with contrast-induced AKI. All 
the patients were consulted before planning intravascu-
lar contrast administration. In each specific case, the risk 
of intervention was assessed. If it was possible to avoid 
this survey, it was canceled, especially if there were un-
correctable risk factors for AKI developing. Such factors 
were: chronic kidney disease with signs of chronic renal 
insufficiency, diabetes, congestive heart failure, recent 
myocardial infarction, age over 75 years. In cases when 
X-ray contrast examination was strongly recommended, 
when conducting nephroprotection, avoidable risk factors 
of the development of contrast-induced AKI were taken 
into account: dehydration, high osmolality of the contrast 
medium, administration of more than 100 ml of contrast, 
recent use of radiocontrast agents, and simultaneous ad-
ministration of other nephrotoxic drugs. 
It was recommended to stop the introduction of diuret-
ics, ACE inhibitors, sartans, statins 24-48 hours before the 
study. If possible, infusion of 0.9% sodium chloride solu-
tion (2 ml/kg/h) and infusion of 4.2% soda-buffer solu-
tion (1 ml/kg/h) were recommended as early as possible 
before the intervention (2-3 hours in advance). In the case 
of an urgent situation, 400 ml of a 0.9% sodium chloride 
solution and 100 ml of a 4.2% soda-buffer solution were 
administered immediately prior to the X-ray vascular ex-
amination. It was also recommended to continue hemo-
dilution with a 0.9% solution of sodium chloride during 
the X-ray contrast test at a rate of 0.5 ml/kg/h (if it wasn`t 
volume overload). In patients with a diuresis rate of less 
than 0.3 ml/kg/h, pulmonary heart disease, hemodilution 
and plasma alkalization were started immediately after 
the X-ray contrast examination at a rate of 0.5 ml/kg/h for 
8-12 hours. Patients with hypernatremia did not undergo 
alkalization of the plasma. It was also recommended that 
acetylcysteine be administered intravenously by stream 
infusion – 5-10 mg/kg before the intervention and 5-10 
mg/kg afterwards. Such prophylaxis proved effective. 
Only 2 patients developed severe AKI, requiring dialy-
sis treatment. In other cases, an increased level of plasma 
creatinine and a decrease diuresis rate were was short-
term and did not require renal replacement therapy.
Thus, when it was necessary to prescribe a particular 
drug, nephroprotection consisted in assessing AKI risk 
factors to avoid nephrotoxic effect. This rule applies to 
most of the groups of medicines used in intensive care: 
antibiotics, anti-tuberculosis drugs, nonsteroidal anti-in-
flammatory drugs, radiocontrast agents, ACE inhibitors, 
diuretics, and antiviral drugs. The following measures 
were considered as nephroprotective measures: choice of 
alternative treatment or examination without a nephro-
toxic drug; the administration of the lowest possible dose 
of the drug (antibiotic, contrast); correction of dehydra-
tion, anemia, and hypotension; providing hemodilution, 
antidote therapy; managing treatment-induced diarrhea, 
active detoxication (early hemodialysis, plasmapheresis, 
extracorporeal antibiotic therapy, ultraviolet blood irradi-
ation). The lethality in the toxic AKI group was 15.8%. 
A 30-day survival rate was 85%. The duration of the 
oligoanuria was 17.2±0.8 days.
Subrenal module of AKI 
The study included 39 patients with subrenal AKI. De-
spite that fact that the patients in this group had been 
sick for a long time before AKI developed, the diagnosis 
when the patients were urgently admitted to hospital was 
not always established. It was because in many cases the 
patients did not seek medical care before their conditi-
on became critical. The main complaints when entering 
the ICU were a lack of urine, nausea, vomiting, diarrhea, 
chills, and inability to breathe deeply. The pain syndro-
me was often absent. Because of an urgent situation, it 
was not always possible to collect a thorough anamnesis. 
Treatment of these patients began with a clarification of 
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a cause of AKI by an ultrasound examination using Dop-
pler scanning.
As a rule, The ultrasound examination revealed an en-
larged calyceal system. In 65% of the cases, there was 
a need for CT examination of the abdominal cavity and 
retroperitoneal space in order to clarify the source of ob-
struction for urine passage. In 87% of the patients, renal 
hemodynamic disorders were not severe. Vps was reduced 
to 64.01±0.25 cm/sec; Ved was 20.3±0.3 cm/sec; the S/D 
ratio was higher than the data in the control group, reach-
ing 3.12±0.08, and RI was up to 0.69±0.02. In 13% of 
the cases, a hemodynamically significant decrease in the 
rates of arterial blood flow and an increase in RI to 0.75 
was recorded, which indicated more severe AKI. Such 
disorders in combination with thick parenchyma did not 
exclude the development of terminal hydronephrosis even 
before a patient’s admission to the ICU. s-NGAL at ad-
mission was higher – 14.56±0.42 ng/ml (13.6±0.8 in the 
control group), although it was significantly (p <0.001) 
lower than in the prerenal and renal AKI patients. At the 
same time, plasma creatinine reached an extremely high 
level of up to 2200 μmol/L; the ureal level went up to 60 
mmol/L. Immediately after the diagnosis was established, 
urinary passage restoration was performed: percutaneous 
nephrostomy (13), stenting (17), open surgery (3), re-
moval of ligatures and restoration of ureteral passability 
(3), bladder and ureteral plastic reconstruction (3). In the 
stage of restoration of diuresis (polyuric phase), massive 
infusion therapy was conducted with balanced polyionic 
solutions (if possible with solutions for hemodiafiltra-
tion). To prevent the development of disequilibrium syn-
drome, 10% and 20% glucose solution was administered 
8-10 ml/kg/day. Dialysis treatment was required for 5 pa-
tients because of terminal hydronephrosis. The mortality 
rate was 5.1%.
To assess the influence of various factors on the outco-
me in AKI patients, a multifactor analysis was carried out. 
The results of treatment in AKI patients were evaluated 
as: the number of those who survived and the number of 
those who died.
When analyzing the risk of development of long-term 
oligoanuria (OA) (“long” means “lasting over 5-days”), 
first, a linear neural network forecasting model was con-
structed using 16 factor variables: age, sex, AKI module 
(pre-renal, renal, subrenal), duration of disease before ad-
mission to the ICU, time of diagnosis, duration of oligo-
anuria in days before admission to the ICU, presence of 
multi-organ disorders, the nature of multi-organ disorders 
(primary, secondary), development of AKI against chron-
ic renal insufficnency, presence of risk factors (no – 0, 
yes – 1), nephroprotection before admission to the ICU 
(0 – was not carried out, 1 – was carried out), conducting 
nephroprotection in the ICU (1 – early, 0 – late), the need 
for hemodialysis (HD) (without HD – 0, with HD – 1), 
the number of hemodialyses, the need for artificial lung 
ventilation, the urea level at admission to the ICU, the 
creatinine level at admission to the ICU, the highest level 
of urea, and the highest level of creatinine.
The sensitivity of the model on the training set was 
90.0% (95% CI 78.5% – 97.4%), and specificity 91.7% 
(95% CI 80.1% – 98.5%). On the confirming set, the sen-
sitivity of the model was 71.4% (95% CI 43.3% – 92.6%), 
and specificity – 93.8% (95% CI 75.4% – 100%).
To identify the factors most associated with the risk of 
developing long-term oligoanuria, the selection of signif-
icant features using the genetic algorithm (GA) method 
was carried out. As a result of the analysis, 3 factors were 
selected: AKI module (prerenal – 1, renal – 2, subrenal 
– 3) (X1), nephroprotection before admission to the ICU 
(0 – was not conducted, 1 – was conducted) (X2), and ne-
phroprotection in the ICU (1 – early, 0 – late) (X3). Using 
the selected set of factor features, a linear neural network 
model for predicting the risk of developing long-term oli-
goanuria was constructed. The sensitivity of this model 
on the training set was 85.0% (95% CI 72.0% – 94.5%), 
specificity was 77.8% (95% CI 62.4% – 90.0%). On the 
confirming set, the sensitivity of this model was 64.3% 
(95% CI 35.8% – 100%), specificity was 81.3% (95% CI 
57.1% – 96.7%).
Sensitivity and specificity on the training and confir-
matory sets are not statistically significant (p = 0.20 and 
p = 0.93, respectively, when comparing by criterion c2), 
which indicates the adequacy of the model constructed.
To evaluate the significance of 3 out of the total 16 
factor factors and to assess the adequacy of the construct-
ed models for predicting the risk of developing long-term 
oligoanuria in the treatment of AKI patients, the method 
of comparing ROC curves was used (Figure 1).
During the analysis, it was established that the area un-
der the ROC curve for the linear neural network model 
Figure 1. ROC curves of models predicting the risk of devel-
opment of long-term OA when treating AKI patients (o – indi-
cates the optimal values of sensitivity and specificity of models 
, the curves are constructed on all 106 cases): 1 – linear neural 
network model built on all 16 factor features, 2 – linear neural 
network a model based on 3 selected factor features
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constructed on all 16 factors was AUC1 = 0.94±0.02, for 
the linear neural network model constructed on the 3 se-
lected factor features, AUC2 = 0 .84±0.04.
Thus, a decrease in the number of factor features from 
16 to 3 does not lead to a significant change in the pre-
dictive qualities of the model, which indicates a high 
significance of the selected factor features (AKI module 
(prerenal – 1, renal – 2, subrenal –3) (X1), nephroprotec-
tion before admission to the ICU (0 –was not conducted, 
1 – was conducted) (X2), nephroprotection in the ICU 
(1 – early, 0 – late) (X3) to predict the risk of long-term 
oligoanuria.
To determine the strength and direction of the influ-
ence of the 3 selected factor features, a logistic regression 
model was constructed; the model is adequate (χ2 = 50.5 
for the number of degrees of freedom k = 4, p<0.001). 
The results of the analysis of the regression coefficients of 
the model are shown in Table 2.
The analysis of logistic regression model coefficients 
implies that in the case of renal AKI module (2), the risk 
of developing long-term oligoanuria (p = 0.001) increa-
ses, OR = 8.7 (95% CI 2.3 –
32.9), compared with the prerenal (1) module. It was 
found that the risk of developing a prolonged oligoanu-
ria reduced statistically significantly (p = 0.032) with 
nephroprotection before admission to the ICU, OR = 
0.3 (95% CI 0.1–0.9). There was also a decrease (p = 
0.014) in the risk of developing long-term oligoanuria 
with early nephroprotection in the ICU, OR = 0.06 (95% 
CI 0.01–0.56).
So, three factor features, associated with the risk of de-
veloping long-term oligoanuria were identified: AKI mo-
dule (prerenal – 1, renal – 2, subrenal – 3) (X1), nephro-
protection before admission to the ICU (0 –  was not 
conducted, 1 – was conducted) (X2), nephroprotection in 
the ICU (1 – early, 0 – late) (X3). The sensitivity of this 
model was 64.3% (95% CI 35.8% – 100%), specificity 
was 81.3% (95% CI 57.1% – 96.7%).
It was established that the risk of developing long-
term oligoanuria in the renal AKI module increases (p = 
0.001), OR = 8.7 (95% CI 2.3–32.9), compared with the 
prerenal (1) AKI module. There was also a decrease (p 
= 0.032) in the risk of developing long-term oligoanuria 
during nephroprotection before admission to the ICU, 
OR = 0.3 (95% CI 0.1–0.9). It was found that in cases of 
early nephroprotection in the ICU, the risk of prolonged 
oligoanuria (p = 0.014) decreases, OR = 0.06 (95% CI 
0.01–0.56).
According to the neural network modeling, the main 
factors influencing the duration of the OA are: the AKI 
module (prerenal, renal, subrenal), early nephroprotective 
measures before admission to the ICU and early nephro-
protection in the ICU. It was also revealed that even later, 
with oliguria having lasted more than 5 days, the adminis-
tration of nephroprotection contributes to shortening the 
duration of OA. This confirms our hypothesis that nephro-
protection should be carried out at all stages of AKI, since 
the severity and extent of renal tubules damage in AKI 
patients can not be evaluated in full, even according to 
objective studies (kidney biopsy, CT examination, ultra-
sound dopplerometry, renography, etc.).
One of the main goals of successful treatment of 
AKI patients is to reduce the duration of oligoanuria. 
The sooner diuresis is restored, the less danger is there 
of MOF development and forming irreversible changes 
in the kidneys. The duration of the OA stage determi-
nes the severity of AKI. The influence of various factors 
was evaluated on the duration of oligoanuria, and it was 
found that carrying out individual pharmacological and 
non-pharmacological nephroprotection reduces the dura-
tion of the oligoanuria stage. 
So, in the comparison group, the oligoanuria stage du-
ration was 22.6±1.2 days. The duration of oligoanuria in 
the main group reliably decreased (p<0.05) to 14.3±0.9 
days.
Conclusions 
Determination of renal blood flow disorders by dopplero-
graphy can improve diagnostics and reveal the immediate 
cause of AKI. This makes it possible to take nephropro-
tective measures in the early stages. Early pharmacolo-
gical and non-pharmacological nephroprotection resulted 
in the shortening of the oligoanuria stage in AKI patients.
The medical technology of individual intensive thera-
py with replacement renal therapy and peridialysis care 
was developed, including: a diagnostic stage with deter-
mination of peculiarities of renal hemodynamic disorders 
and pharmacological and instrumental (stenting, draina-
ge, etc.) correction of the main cause and manifestations 
of AKI.
Improving the diagnosis and carrying out the individu-
al pharmacological and non-pharmacological nephropro-
tection provides an improvement in the results of treat-
ment in AKI patients.
Table 2. Coefficients of the 3-factor model of long-term oliguria risk prediction (logistic regression model)
Factor feature Prediction model coefficients, 
b±m
Significance of the coefficient 
difference from 0, p
Odds ratio, OR (95% CI 
OR)
X1 (2) vs (1) 2.2±0.7 0.001* 8.7 (2.3–32.9)
X1 (3) vs (1) 0.3±0.6 0.684 –
X2 -1.2±0.5 0.032* 0.3 (0.1–0.9)
X3 -2.8±1.1 0.014* 0.06 (0.01–0.56)
Note: * – the difference from 0 is statistically significant, p <0.05
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